SOURCE: Chiome Bioscience Inc.

Chiome Bioscience Inc.

October 26, 2009 13:16 ET

Chiome Bioscience to Present at "Antibody Partnering & Technology Summit" in San Francisco on 29 October 2009

Chiome's ADLib® System Rapidly Generates High-Affinity Monoclonal Antibodies Against GPCRs, Lipids, Peptides and Sugar Chains

TOKYO--(Marketwire - October 26, 2009) - Chiome Bioscience Inc., a therapeutic monoclonal-antibody platform company based in Tokyo, Japan, announced today its upcoming North American conference participation. Chiome owns the exclusive rights to the ADLib® System, an innovative and proprietary technology for antibody generation in vitro that leverages gene conversion to rapidly produce monoclonal antibodies against recalcitrant targets such as lipids, sugar chains, peptides and transmembrane proteins such as GPCRs. Acceleration of highly diverse gene conversion is the central mechanism of the ADLib® system and is based on activation of homologous recombination at the immunoglobulin locus by histone acetylation -- thus leading to generation of highly diverse antibody libraries in vitro in only two weeks.

Chiome's conference presentation schedule includes the following major events:

(1) GTCbio's "Antibody Partnering & Technology Summit"

29-30 October 2009, Hotel Nikko, San Francisco, Calif.

(2) IBC's "Antibody Engineering & Antibody Therapeutics"

06-10 December 2009, San Diego, Calif.

(3) BioPartnering North America

24-26 January 2010, Vancouver, BC

Dr. Masa Fujiwara, President & CEO of Chiome Bioscience, remarked: "We are very pleased to present at GTCbio's "Antibody Partnering & Technology Summit" in San Francisco this week, the first therapeutic-antibody partnering conference to bring together high-level executives in equal proportions from both management and R&D in a single-track program."

David Palella, President of BioScience Ventures Inc. and co-chair of the conference, added: "This novel conference format should augment and accelerate partnering opportunities for all the presenting and attending companies. In particular, Chiome looks forward to adding to its current complement of world-class ADLib® collaborators: The China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR) in Shanghai, China; and Chugai Pharmaceutical Co. Ltd. In Tokyo, Japan (an affiliate of F. Hoffmann - La Roche Ltd.)."

For more information about Chiome Bioscience, please visit the web site at:

Contact Information

  • Contacts:

    Mr. Shigeru KOBAYASHI
    Senior Director
    Business Development
    Riken - Wako Incubation Plaza 203
    2-3-13, Minami
    Wako, Saitama 351-0104

    main tel: +81-48-452-6698
    cell: +81-90-3693-4651
    fax: +81-48-450-6460
    Email Contact


    David A. Palella
    BioScience Ventures Inc.
    (Business Development Advisor to Chiome)
    San Diego, California
    Tel: 858-793-0741
    Email Contact